Suggestions
Katherine Harris
Chief Development Officer | Board Director
Katherine Harris is a prominent figure in the field of antibody research and development, currently serving as a Board Member of The Antibody Society. Here's a comprehensive overview of her professional background and involvement with the organization:
Professional Experience
Katherine Harris is currently the Chief Development Officer (CDO) at Rondo Therapeutics, a position she has held since February 2023.3 In this role, she:
- Leads IND-enabling activities, including CMC, toxicology, pharmacology, DMPK, and regulatory aspects
- Provides strategic guidance on target selection and program prioritization
- Oversees non-clinical development plans from candidate nomination through IND submission
- Manages external partnerships related to non-clinical development
Prior to her current position, Harris held several leadership roles in the biotechnology industry:
- Vice President of Discovery at Amgen (October 2021 - February 2023)
- Vice President and Senior Director of Discovery at Teneobio, Inc. (2017 - 2021)
- Senior Research Scientist at Teneobio, Inc. (2015 - 2017)
- Research Scientist at Panoply Bio and SwitchGear Genomics (2011 - 2015)
Education
Harris holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley (2001-2007) and a B.S. in Biology from the University of Missouri-Kansas City (1999-2000).3
Involvement with The Antibody Society
Katherine Harris has been actively involved with The Antibody Society in various capacities:
-
Board Member: Recently elected to the Board of Directors of The Antibody Society.56
-
Vice President: Serving as the Vice President of The Antibody Society for the 2024-25 term.1
-
Meetings Committee Chair: Harris chairs the Meetings Committee of The Antibody Society.27
-
Scientific Advisor: She serves as a scientific advisor for the Antibody Engineering & Therapeutics Europe conference.2
In her role with The Antibody Society, Harris contributes to the organization's mission of advancing antibody research and development. Her expertise in IND-enabling activities and preclinical drug development is particularly valuable to the society's goals.45
Katherine Harris's LinkedIn username is indeed "katharris".3
